Patents by Inventor Roman Szweda

Roman Szweda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rapamycin carbohydrate derivatives
    Patent number: 7160867
    Abstract: This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: January 9, 2007
    Assignee: Isotechnika, Inc.
    Inventors: Mark Abel, Roman Szweda, Daniel Trepanier, Randall W Yatscoff, Robert T. Foster
  • Rapamycin carbohydrate derivatives
    Publication number: 20060079466
    Abstract: This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.
    Type: Application
    Filed: September 15, 2005
    Publication date: April 13, 2006
    Inventors: Mark Abel, Roman Szweda, Daniel Trepaier, Randall Yatscoff, Robert Foster
  • Rapamycin carbohydrate derivatives
    Publication number: 20040235762
    Abstract: This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.
    Type: Application
    Filed: May 13, 2004
    Publication date: November 25, 2004
    Inventors: Mark Abel, Roman Szweda, Daniel Trepanier, Randall W. Yatscoff, Robert T. Foster
  • Modified .alpha.-D-Glc.rho.-(1-2)-.alpha.-D-Glc.rho.-(1-3)-.alpha.-D-Glc.rho.-ana logues
    Patent number: 5929037
    Abstract: Disclosed is the trisaccharide .alpha.-D-Glcp-(1-2)-.alpha.-D-Glcp-(1-3)-.alpha.-D-Glcp and compounds related thereto as well as pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 27, 1999
    Assignee: Alberta Research Council
    Inventors: Om Srivastava, Roman Szweda
  • Modified kojibioside analogues
    Patent number: 5877157
    Abstract: Disclosed are novel analogues of kojibiose and pharmaceutical compositions comprising such analogues.
    Type: Grant
    Filed: March 7, 1997
    Date of Patent: March 2, 1999
    Assignee: Alberta Research Council
    Inventors: Om Srivastava, Roman Szweda, Ulrike Spohr
  • Oligosaccharide glycosides having mammalian immunosuppresive and tolerogenic properties
    Patent number: 5874411
    Abstract: Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a mammal.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: February 23, 1999
    Assignee: Glycomed Incorporated
    Inventors: Om P. Srivastava, Geeta Srivastava, Roman Szweda, David R. Bundle, Ole Hindsgaul, H. Rizk Hanna, Kevin Holme, Frank W. Barresi, Minghui Du
  • Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen
    Patent number: 5814616
    Abstract: The present invention is directed to methods of reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the administration of valienamine-related disaccharide compounds and the pharmaceutical compositions employed in the method.
    Type: Grant
    Filed: November 5, 1996
    Date of Patent: September 29, 1998
    Assignee: Alberta Research Council
    Inventors: Om P. Srivastava, Roman Szweda, Richard H. Smith, Robert M. Ippolito, Ulrike Spohr
  • Modified kojibiosides analogues
    Patent number: 5633233
    Abstract: Disclosed are novel analogues of kojibiose and pharmaceutical compositions comprising such analogues.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 27, 1997
    Assignee: Alberta Research Council
    Inventors: Om Srivastava, Roman Szweda, Ulrike Spohr
  • Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen
    Patent number: 5571796
    Abstract: The present invention is directed to methods of reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the administration of valienamine-related disaccharide compounds and the pharmaceutical compositions employed in the method.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 5, 1996
    Assignee: Alberta Research Council
    Inventors: Om P. Srivastava, Roman Szweda, Richard H. Smith, Robert M. Ippolito, Ulrike Spohr